| Wissenschaftl. Titel | A Phase 1, First-in-human (FIH), Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors, That Relapsed Post or Were Refractory to a Prior Anti-PD-1/PD-L1 Therapy and Have Exhausted All Available Approved Standard Treatments or Are Not Eligible for Them Anymore (the "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Effector Cell Relocation) |
| Erkrankung |
Solide Tumore/Neoplasien:
Verschiedene solide Tumore/Neoplasien:
Zweitlinie oder später
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (W) Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 14.07.2021 Data entry XI CCP
geändert 14.07.2021 Data entry XI CCP